Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Gadolin Research LLC

Neither a doctor nor a teaching hospital

Research payments

$24,591,848

384 payments

Through program year 2025, Gadolin Research LLC is reported as receiving $24,591,848 in research payments, across 384 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,171,196 48
2024 Research $4,283,674 43
2023 Research $5,918,137 85
2022 Research $6,118,256 39
2021 Research $3,766,288 46
2020 Research $1,568,213 75
2019 Research $766,084 48

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $20,719,569 59 payments
  2. Pfizer Inc. $2,582,931 93 payments
  3. Supernus Pharmaceuticals, Inc. $400,377 50 payments
  4. GlaxoSmithKline, LLC. $273,841 36 payments
  5. Moderna TX, Inc. $159,912 87 payments
  6. AbbVie, Inc. $124,828 7 payments
  7. Genentech, Inc. $94,245 10 payments
  8. Sumitomo Pharma America, Inc. $86,704 16 payments
  9. Myovant Sciences GmbH $56,079 3 payments
  10. Organon LLC $44,787 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $4,178,169 9 payments
  2. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $2,908,197 4 payments
  3. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $2,668,281 5 payments
  4. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $2,593,894 2 payments
  5. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $2,049,822 2 payments
  6. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $1,959,184 4 payments
  7. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $1,653,589 59 payments
  8. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $1,244,995 6 payments
  9. A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women $894,055 29 payments
  10. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $798,906 3 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $139,043 17 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record